Recent Updates
Recently added Catalysts
HROW Positive Sentiment Score: 70/100

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Key Takeaway: Harrow (Nasdaq: HROW) will report its second quarter financial results on August 10, 2026, after market close. A conference call will be held on August 11, 2026, at 8:00 a.m. ET to discuss these results and provide a business update. The financial results will be available on their website along with a Letter to Stockholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Harrow is set to report its financial results, indicating ongoing business activity.
  • The company is actively engaging with investors through a conference call.
  • Harrow's commitment to ophthalmic disease management showcases its dedication to healthcare.

Full Press Release Details

NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second quarter ended June 30, 2026, on Monday, August 10, 2026, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 11, 2026, to discuss the results and provide a business update.
Conference Call Information Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact: Mike Biega VP of Investor Relations & Communications mbiega@harrowinc.com 617-913-8890

Frequently Asked Questions

When will Harrow report its Q2 2026 financial results?

Harrow will report its Q2 2026 financial results on August 10, 2026.

What time is the conference call for Harrow's results?

The conference call will take place at 8:00 a.m. ET on August 11, 2026.

Where can I access Harrow's financial results?

The financial results will be posted on the 'Investors' section of Harrow's website.

How can I participate in Harrow's conference call?

Participants can register in advance to receive a unique dial-in number and PIN.

Last updated: Jul 27, 2026